Cryptococcosis in patients with hematological diseases: a 14-year retrospective clinical analysis in a Chinese tertiary hospital

BMC Infect Dis. 2017 Jul 3;17(1):463. doi: 10.1186/s12879-017-2561-z.

Abstract

Background: Cryptococcal infection has become a public health challenge globally. However, information about cryptococcal infection in patients with hematological diseases remains relatively rare.

Methods: HIV-uninfected cryptococcosis cases with hematological diseases admitted to Huashan Hospital from January 2001 to December 2014 were reviewed.

Results: In total, 33 cryptococcosis patients were enrolled, including 12 malignant and 21 non-malignant hematological cases. Twenty-six patients had central nervous system (CNS) involvement, which was observed more often in patients with non-malignancies than with malignancies (20/21 vs. 6/12, P = 0.001) Most patients (25/26) with CNS infection were confirmed by cerebrospinal fluid (CSF) culture or smear, and 100% (20/20) of them tested positive for the CSF cryptococcal antigen test. Eighteen out of 26 cryptococcal meningitis patients were treated with amphotericin B (AmB)-based therapy, 16 of them with AmB deoxycholate (d-AmB) and 2 patients with liposomal AmB. The clinical success rate was 55.6%. D-AmB was well-tolerated at 0.35-0.59 mg/kg/d (median 0.43 mg/kg/d) and only 12 patients had mild adverse events.

Conclusions: CNS cryptococcal infection was more frequent in patients with hematological non-malignancies, and cryptococcal antigen test as well as the CSF fungal culture or smear are suggested for early diagnosis. D-AmB could be used as an alternative therapy for CNS-infected patients with hematological diseases.

Keywords: Cryptococcal meningitis; Cryptococcosis; HIV-uninfected; Hematological diseases; Pulmonary cryptococcosis.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use*
  • Central Nervous System Fungal Infections / drug therapy
  • Central Nervous System Fungal Infections / microbiology
  • Cryptococcosis / drug therapy
  • Cryptococcosis / etiology*
  • Deoxycholic Acid / therapeutic use
  • Drug Combinations
  • Female
  • Hematologic Diseases / complications
  • Hematologic Diseases / microbiology*
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / microbiology
  • Humans
  • Male
  • Meningitis, Cryptococcal / drug therapy
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Tertiary Care Centers
  • Young Adult

Substances

  • Antifungal Agents
  • Drug Combinations
  • liposomal amphotericin B
  • Deoxycholic Acid
  • Amphotericin B
  • amphotericin B, deoxycholate drug combination